Skip to main content
. Author manuscript; available in PMC: 2019 Nov 13.
Published in final edited form as: AIDS. 2018 Nov 13;32(17):2525–2531. doi: 10.1097/QAD.0000000000002002

Table 2.

Genital HSV total and subclinical shedding rates, median HSV DNA detected, and days with lesions by ART use.

ART status N (# sessions) Total (%) Median HSV DNA (log10 copies/mL) Subclinical (%) Days with reported lesions (%)
Not on
ART
25 298/1538 (19.4%) 5.02 208/1360 (15.3%) 193/1749 (11.0%)
ART initiated
<90 days
6 155/512 (30.2%) 5.84 115/454 (25.3%) 61/540 (11.3%)
ART >3 months 74 1019/4375 (23.3%) 4.81 880/4149 (21.2%) 256/4679 (5.5%)